Skip to main content

CARACTERIZACION FUNCIONAL DE DOMINIOS MESOSCOPICOS DE SUPERFICIE ENDOTELIAL REGULADOS POR LA SUBFAMILIA RHOA DE GTPASAS DURANTE LA RESPUESTA INFLAMATORIA

PID2020-119881RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Harnessing homeostatically active RhoC at cell junctions preserves human endothelial barrier function during inflammation

  • Colás-Algora, Natalia
  • Muñoz-Pinillos, Pablo
  • Barroso, Susana
  • Cacho-Navas, Cristina
  • Caballero, Álvaro
  • Cerro-Tello, Gema
  • Rivas, Gema de
  • González-Fernández, Martin
  • Jimenez-Alfaro, Ignacio
  • Fresno, Manuel
  • Ribas, Catalina
  • Paradela, Alberto
  • López-Collazo, Eduardo
  • Fernández, José-Jesús
  • Millán, Jaime
The GTPase RhoA plays a critical role in generating actomyosin-mediated contractile forces that cause endothelial hyperpermeability during systemic inflammatory diseases. RhoA is almost identical to RhoB and RhoC, all of which are molecular targets of specific bacterial toxins. Searching for new treatments to modulate Rho-dependent endothelial integrity, we demonstrate that the selective and simultaneous activation of these three Rho GTPases with a chimeric recombinant toxin does not induce cell contraction but enhances microvascular endothelial barrier function in response to pathological inflammatory challenges in vitro and in vivo. This pro-barrier effect is specifically mediated by RhoC, whose activity is increased by cell confluence. The uniqueness of RhoC relies on an arginine residue (R188) within its hypervariable region that determines its junctional localization, high homeostatic activity, and barrier-protective function, in contrast to the permeability-inducing, low homeostatic activity of RhoA and RhoB. Quantitative proteomics and high-resolution confocal microscopy revealed that RhoC regulates perijunctional actomyosin and the expression of myosin light chain proteins. Thus, harnessing the activity of RhoC represents a potential therapy for strengthening endothelial barriers during pathological inflammation., The expert technical advices of the confocal microscopy, electron microscopy, genomic and animal facilities are gratefully acknowledged. The work was supported by grants PID2020-119881RB-I00 from AEI (to CC-N, PM-P, NC-A, SB, GdR, GC-T, and JM) and Grant TomoXliver2, Ref: S2022/BMD-7232 funded by Comunidad Autónoma de Madrid. (to SB and JM), and IND2019/BMD-17139 (to GC-T and JM) from Comunidad de Madrid. This research work was also funded by the European Commission─NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) (to JM). SB is also supported by Endocornea2, Convenio Colaboración CSIC, funded by Instituto de Investigación Fundación Jiménez Díaz. The authors also thank Dr Phil Mason, who provided English language support., No